Richard Conway

Research interests

Publications

• EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

  Annals of the Rheumatic Diseases · 2022 · 10.1136/annrheumdis-2021-222006

• COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

  Nature Reviews Rheumatology · 2022 · 10.1038/s41584-022-00755-x

• Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

  RMD Open · 2021 · 10.1136/rmdopen-2021-001814

• SARS – CoV ‐2 Infection and COVID ‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis

  Arthritis & Rheumatology · 2021 · 10.1002/art.42030

• Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

  UCL Discovery (University College London) · 2021

• JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

  Journal of Inflammation Research · 2020 · 10.2147/jir.s219586

• Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature

  Lara D. Veeken · 2019 · 10.1093/rheumatology/kez337

• Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment

  Frontiers in Medicine · 2019 · 10.3389/fmed.2019.00238

• Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial

  Seminars in Arthritis and Rheumatism · 2018 · 10.1016/j.semarthrit.2018.04.004

• Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis

  Journal of Clinical Medicine · 2018 · 10.3390/jcm8010015

• High Risk Subgroups Sensitive to Air Pollution Levels Following an Emergency Medical Admission

  Toxics · 2017 · 10.3390/toxics5040027

• 2016 update of the EULAR recommendations for the management of early arthritis

  Annals of the Rheumatic Diseases · 2017 · https://doi.org/10.1136/annrheumdis-2016-210602

• Risk of liver disease in methotrexate treated patients

  World Journal of Hepatology · 2017 · 10.4254/wjh.v9.i26.1092

• Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials

  The Journal of Rheumatology · 2016 · 10.3899/jrheum.150674

• Ustekinumab for the treatment of refractory giant cell arteritis

  Annals of the Rheumatic Diseases · 2016 · 10.1136/annrheumdis-2016-209351

• Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

  BMJ · 2015 · 10.1136/bmj.h1269

• Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials

  Seminars in Arthritis and Rheumatism · 2015 · 10.1016/j.semarthrit.2015.05.003

• Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials

  Arthritis & Rheumatology · 2013 · 10.1002/art.38322

• Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

  Journal of Cystic Fibrosis · 2011 · 10.1016/s1569-1993(11)60011-8

• Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials

  Journal of Cystic Fibrosis · 2011 · 10.1016/s1569-1993(11)60012-x

• Transmission of colistin‐resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center

  Pediatric Pulmonology · 2002 · 10.1002/ppul.10166

Current projects

No projects listed.